Business Description
CellaVision AB
ISIN : SE0000683484
Share Class Description:
LTS:0MR5: Bearer ShsTotal Employee Number:
253Compare
Compare
Traded in other countries / regions
CEVI.Sweden0MR5.UKCLVSF.USAC26.Germany IPO Date
2016-06-09Description
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.29 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | 0.32 | |||||
Interest Coverage | 68.45 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 9.37 | |||||
Beneish M-Score | -2.7 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.9 | |||||
3-Year EBITDA Growth Rate | 7.2 | |||||
3-Year EPS without NRI Growth Rate | 9 | |||||
3-Year FCF Growth Rate | 19 | |||||
3-Year Book Growth Rate | 11.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.81 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.29 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 59.56 | |||||
9-Day RSI | 60.04 | |||||
14-Day RSI | 59.05 | |||||
3-1 Month Momentum % | 20.74 | |||||
6-1 Month Momentum % | -6.06 | |||||
12-1 Month Momentum % | -14.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.31 | |||||
Quick Ratio | 2.33 | |||||
Cash Ratio | 1.3 | |||||
Days Inventory | 186.72 | |||||
Days Sales Outstanding | 56.06 | |||||
Days Payable | 61.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.85 | |||||
Dividend Payout Ratio | 0.51 | |||||
3-Year Dividend Growth Rate | 7.7 | |||||
Forward Dividend Yield % | 1.85 | |||||
5-Year Yield-on-Cost % | 1.85 | |||||
Shareholder Yield % | 1.87 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 68.71 | |||||
Operating Margin % | 22.23 | |||||
Net Margin % | 17.46 | |||||
EBITDA Margin % | 22.42 | |||||
FCF Margin % | 13.28 | |||||
OCF Margin % | 23.35 | |||||
ROE % | 14.8 | |||||
ROA % | 11.75 | |||||
ROIC % | 14.78 | |||||
3-Year ROIIC % | 24.77 | |||||
ROC (Joel Greenblatt) % | 65.63 | |||||
ROCE % | 17.01 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 27.31 | |||||
Forward PE Ratio | 25.04 | |||||
PE Ratio without NRI | 27.31 | |||||
Shiller PE Ratio | 26.97 | |||||
Price-to-Owner-Earnings | 93.41 | |||||
PEG Ratio | 3.25 | |||||
PS Ratio | 4.76 | |||||
PB Ratio | 3.98 | |||||
Price-to-Tangible-Book | 10.43 | |||||
Price-to-Free-Cash-Flow | 35.9 | |||||
Price-to-Operating-Cash-Flow | 20.42 | |||||
EV-to-EBIT | 21.93 | |||||
EV-to-Forward-EBIT | 19.92 | |||||
EV-to-EBITDA | 21.93 | |||||
EV-to-Forward-EBITDA | 15.59 | |||||
EV-to-Revenue | 4.92 | |||||
EV-to-Forward-Revenue | 4.48 | |||||
EV-to-FCF | 33.23 | |||||
Price-to-GF-Value | 0.78 | |||||
Price-to-Projected-FCF | 1.89 | |||||
Price-to-DCF (Earnings Based) | 1.35 | |||||
Price-to-DCF (FCF Based) | 2.46 | |||||
Price-to-Median-PS-Value | 0.41 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.87 | |||||
Price-to-Graham-Number | 3.55 | |||||
| Price-to-Net-Current-Asset-Value | 19.35 | |||||
Earnings Yield (Greenblatt) % | 4.55 | |||||
FCF Yield % | 2.62 | |||||
Forward Rate of Return (Yacktman) % | 10.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CellaVision AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 739.15 | ||
| EPS (TTM) (kr) | 5.41 | ||
| Beta | 0.6982 | ||
| 3-Year Sharpe Ratio | -0.23 | ||
| 3-Year Sortino Ratio | -0.33 | ||
| Volatility % | 29.66 | ||
| 14-Day RSI | 59.05 | ||
| 14-Day ATR (kr) | 3.100545 | ||
| 20-Day SMA (kr) | 142.615 | ||
| 12-1 Month Momentum % | -14.66 | ||
| 52-Week Range (kr) | 118.8 - 188.4 | ||
| Shares Outstanding (Mil) | 23.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CellaVision AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CellaVision AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-05 11:00 | In 183 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-05 07:20 | In 183 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 11:00 | In 92 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 07:20 | In 92 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-17 11:00 | 135.70 (+1.57%) | ||
| Second quarter earnings results for 2026 | 2026-07-17 07:20 | 135.70 (+1.57%) | ||
| SEK 2.750000 Cash Dividend | 2026-04-29 | 127.20 (+4.43%) | ||
| General meeting for 2026 | 2026-04-28 15:00 | 121.20 (-1.14%) | ||
| First quarter earnings conference call for 2026 | 2026-04-24 11:00 | 153.70 (-1.22%) | ||
| First quarter earnings results for 2026 | 2026-04-24 07:20 | 153.70 (-1.22%) |
Show
Entries
CellaVision AB Frequently Asked Questions
What is CellaVision AB(LTS:0MR5)'s stock price today?
The current price of LTS:0MR5 is kr148.60. The 52 week high of LTS:0MR5 is kr188.40 and 52 week low is kr118.80.
When is next earnings date of CellaVision AB(LTS:0MR5)?
The next earnings date of CellaVision AB(LTS:0MR5) is 2026-11-06 Est..
Does CellaVision AB(LTS:0MR5) pay dividends? If so, how much?
The Dividend Yield %  of CellaVision AB(LTS:0MR5) is 1.85% (As of Today), Highest Dividend Payout Ratio of CellaVision AB(LTS:0MR5) was 0.6. The lowest was 0.14. And the median was 0.4. The  Forward Dividend Yield % of CellaVision AB(LTS:0MR5) is 1.85%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on CellaVision AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers